

Amendments to the Claims:



Listing of the Claims:

Claims 1-4 (canceled)

Claim 5 (original): A method for the treatment of sleep apnea in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a somatostatin analogue selected from KE108 and a somatostatin analogue of formula I -(D/L)Trp-Lys-X₁-X₂-


I

wherein X₁ is a radical of formula (a) or (b)



wherein R₁ is optionally substituted phenyl, wherein the substituent may be halogen, methyl, ethyl, methoxy or ethoxy,

R₂ is -Z₁-CH₂-R₁, -CH₂-CO-O-CH₂-R₁,



wherein Z₁ is O or S, and

X₂ is an α -amino acid having an aromatic residue on the C_α side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His,(Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys⁹ of the native somatostatin-14, or a pharmaceutically acceptable salt thereof.

Claim 6 (original): A method for improving cardiorespiratory function, particularly during sleep, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a somatostatin analogue as defined in claim 5 or a pharmaceutically acceptable salt thereof.

Claim 7 (original): A method for improving airflow in upper airways, particularly during sleep, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a somatostatin analogue as defined in claim 5 or a pharmaceutically acceptable salt thereof.

Claim 8 (original): A method for promoting paradoxical sleep in a subject in need thereof, e.g. in an elderly subject, comprising administering to said subject a therapeutically effective amount of a somatostatin analogue as defined in claim 5 or a pharmaceutically acceptable salt thereof.

Claim 9 (currently amended): A pharmaceutical composition ~~for use in any method according to any one of claims 5 to 8~~ comprising a the somatostatin analogue of formula I as specified in claim 5 according to claim 5 or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable diluents or carriers therefor.

Claim 10 (currently amended): ~~Use, The method or composition according to any one of claims 1 to 9~~ claim 5, wherein the somatostatin analogue comprising an amino acid sequence of formula I is cyclo[{4- (NH₂-C₂H₄-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.